Physician profile

Eugene M Parent

Cardiovascular Disease · Bradenton, FL

NPI 1437135621

$301,619.13

in general payments reported to CMS, 2019-2025

37 companies · $8,015 in 2025

The $8,015 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$66,426.60
Consulting Fee$8,500.00
Food and Beverage$7,745.82
Travel and Lodging$5,841.20

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $108,940.44 2019-2025 Jardiance
Abbott Laboratories $85,987.13 2019-2025 Mitraclip, Amplatzer Talisman, Triclip
Lilly USA, LLC $71,295.86 2019-2025 Jardiance
Boston Scientific Corporation $30,300.33 2019-2025 Watchman Access System, Watchman Flx, General - Brady
Edwards Lifesciences Corporation $1,277.00 2024-2025 Evoque, Pascal
Medtronic Vascular, INC. $895.13 2019
Cvrx, INC. $452.04 2023-2025 Barostim Neo System
Inari Medical, INC. $323.60 2023-2024 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Alnylam Pharmaceuticals INC. $309.83 2024-2025 Amvuttra, Onpattro
Heartflow, INC. $222.51 2019-2022
Novartis Pharmaceuticals Corporation $220.84 2022-2025
Astrazeneca Pharmaceuticals LP $138.82 2019-2024 Farxiga
Sanofi-Aventis U.S. LLC $137.88 2019
Abiomed $120.91 2023 Impella
Pfizer INC. $113.18 2019-2025
Show all 37 companies
CompanyGeneral paymentsYearsTop products
Penumbra, INC. $112.40 2023 Indigo System
Amgen INC. $96.61 2019-2025 Repatha, Repatha
Janssen Pharmaceuticals, INC $93.38 2021-2024 Xarelto
Philips North America LLC $92.92 2022-2024 (Ck4) Mcot
Novo Nordisk INC $67.09 2019-2025 Wegovy, Rybelsus, Ozempic
Biosense Webster, INC. $52.02 2022-2024 Carto 3
Merck Sharp & Dohme LLC $44.98 2023 Verquvo
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $42.09 2019-2022
Medtronic, INC. $39.23 2023 Mycarelink
Biotronik INC. $24.98 2020
Preventice Services, LLC $24.92 2021
Arineta, INC $24.42 2021
Regeneron Healthcare Solutions, INC. $23.35 2019
Amarin Pharma, INC. $19.96 2020
Irhythm Technologies, INC. $18.25 2024 Zio Monitor, Zio Xt Patch
Medicomp INC $17.17 2019
Esperion Therapeutics, INC. $16.72 2021
Kowa Pharmaceuticals America, INC. $15.76 2021
Actelion Pharmaceuticals US, INC. $15.38 2019
Ge Healthcare $15.25 2021
Stryker Corporation $13.78 2025 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Astellas Pharma US INC $12.97 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Eugene M Parent

$301,619.13

in general payments reported 2019-2025

Years
2019-2025
Top company
Boehringer Ingelheim Pharmaceuticals, INC.
Context
The $8,015 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/574546/eugene-m-parent

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.